Geographic Inequalities in Myeloma
Myeloma UK is inviting applications to answer questions about geographic inequalities in myeloma. We will award up to £100K to one research project to review the current landscape and produce an evidence base to help Myeloma UK improve outcomes for patients.
Research Objectives
The research project will provide evidence and increase understanding of the services myeloma patients and their family members have access to across the UK and how this impacts patient outcomes.
The objectives of this research call are to:
- Understand what services myeloma patients and their families have access to at the local and regional levels across the UK.
- Understand how local service access impacts myeloma patient outcomes including patient quality of life.
Call details and how to apply
Date call opens: Monday 1st June 2020
Deadline date: 3pm – Thursday 24th September 2020
Maximum funding limit: £100K
Maximum project duration:18 Months
Eligibility: The Principal Investigator must hold a permanent post at either a UK Higher Education Institute or the NHS.
Before you begin your application please ensure that you read the Call details and Guidance for applicants which can be found under supporting documents below. To apply please complete the Health Services Research Grant application form which can also be found under supporting documents below.
Completed applications should be emailed to research@myeloma.org.uk by the deadline. Applications received after the deadline will not be considered.If you have any questions about this call or eligibility, please contact us by emailing research@myeloma.org.uk
Peer review
Myeloma UK is an Association of Medical Research Charities (AMRC) member charity and adheres to the principle of peer review as set out by the AMRC. All competitive research applications received by the deadline will be peer reviewed in accordance with the Myeloma UK Peer Review Policy.
Acknowledgement of Support
Takeda UK Ltd. and Sanofi UK have funded the Myeloma Geographical Equalities Audit but have had no editorial control over the content/outputs. Takeda UK Ltd. has also supported the Myeloma Geographical Equalities Audit as an active member of the strategic advisory group.
